<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Peritoneal dialysis solutions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Peritoneal dialysis solutions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Peritoneal dialysis solutions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Muhammad Alam, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle W Krause, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although the ancient Egyptians were the first to describe the peritoneal cavity in approximately 3000 BC, the concept of peritoneal dialysis is relatively new. In the late 19<sup>th</sup> century, Wegner, a German investigator, was the first to use peritoneal solutions in animals; he reported that hypertonic solutions increased in volume when injected into the peritoneal cavity. Additional investigations found that hypertonic solutions increased and hypotonic solutions decreased peritoneal fluid volume [<a href="#rid1">1</a>].</p><p>Various different investigators subsequently evaluated the efficacy of treating uremia by instilling fluids into the peritoneal cavity:</p><p class="bulletIndent1"><span class="glyph">●</span>Gantar instilled <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solution in the peritoneal cavity of uremic guinea pigs and subsequently treated a uremic woman with peritoneal dialysis solution containing saline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heusser added dextrose to the peritoneal dialysis solution to improve ultrafiltration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 1938, Rhoads added lactate to the peritoneal dialysis fluid to correct acidosis.</p><p></p><p>Several <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> were subsequently used in the management of uremic patients. Besides <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, they included glucose solutions, gelatin, xylitol, <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, glucose polymer (eg, <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>), amino acids, and many other agents [<a href="#rid2">2-5</a>].</p><p>The Dan Baxter Company made the first commercial dialysis solution available in 1959. Subsequently, there has been very little change in the basic composition of these solutions. A review of <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> will be presented in this topic review.</p><p class="headingAnchor" id="H2"><span class="h1">IDEAL SOLUTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a> consist of water, osmotic agents, electrolytes, and minerals and are sometimes fortified with different substances. An ideal solution should [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Have a sustained and predictable solute clearance with minimal absorption of the osmotic agents</p><p class="bulletIndent1"><span class="glyph">●</span>Provide deficient electrolytes and nutrients if required</p><p class="bulletIndent1"><span class="glyph">●</span>Correct acid-base problems without interacting with other solutes in the peritoneal dialysis fluid</p><p class="bulletIndent1"><span class="glyph">●</span>Be free of and inhibit the growth of pyrogens and micro-organisms</p><p class="bulletIndent1"><span class="glyph">●</span>Be free of toxic metals</p><p class="bulletIndent1"><span class="glyph">●</span>Be inert to the peritoneum</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CONSTITUENTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a> have not significantly changed since they were made available commercially in 1959. The earlier solutions were packaged in glass bottles, but they are currently available in several sizes of collapsible plastic bags. The constituents can be broadly divided into osmotic agents, buffers, and electrolytes [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Osmotic agents</span><span class="headingEndMark"> — </span>Fluid removal is essential in dialysis patients. Osmotic agents, being hyperosmolar, allow net water removal by altering the osmotic pressure gradient between the peritoneal dialysis solution and plasma water (see  <a class="medical medical_review" href="/d/html/1878.html" rel="external">"Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis"</a>). The initial <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> were <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solutions, but, since the 1940s, <strong>dextrose</strong> has been commonly used as the osmotic agent. Several investigators have attempted to use other osmotic agents in peritoneal dialysis solutions but have been unable to show any better overall performance.</p><p>Properties of an ideal osmotic agent include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolized easily with nontoxic degradation products</p><p class="bulletIndent1"><span class="glyph">●</span>Poorly absorbed</p><p class="bulletIndent1"><span class="glyph">●</span>Inert and nontoxic to the peritoneal membrane</p><p class="bulletIndent1"><span class="glyph">●</span>Inexpensive</p><p class="bulletIndent1"><span class="glyph">●</span>Effective osmotic agent at low concentration</p><p class="bulletIndent1"><span class="glyph">●</span>No metabolic consequences of absorption</p><p class="bulletIndent1"><span class="glyph">●</span>Must be of nutritional value if absorbed</p><p class="bulletIndent1"><span class="glyph">●</span>Not difficult to manufacture</p><p class="bulletIndent1"><span class="glyph">●</span>Should not inhibit peritoneal defenses</p><p></p><p>The two major types of osmotic agents that are used in peritoneal dialysis are generally classified as agents with high or low molecular weight.</p><p class="headingAnchor" id="H5"><span class="h3">High-molecular-weight agents</span><span class="headingEndMark"> — </span>High-molecular-weight agents, such as glucose polymers, polypeptides, dextran, gelatin, and polycations, range in weight from 20,000 to 350,000 DA. With these agents, a high concentration is required to produce an osmolar gradient, which could lead to hyperviscosity, thereby affecting dialysis inflow and outflow.</p><p class="headingAnchor" id="H125248406"><span class="h4">Glucose polymer-containing solutions (icodextrin)</span><span class="headingEndMark"> — </span>Glucose polymers (eg, <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>) are mixtures of oligo/polysaccharides of variable chain lengths. Initially, low-molecular-weight oligo/polysaccharides with weights of approximately 900 DA were tried with limited success. Larger molecules with weights of 20,000 DA have been introduced in Europe [<a href="#rid8">8</a>]. Icodextrin dialysate (Extraneal) is the major glucose polymer utilized in peritoneal dialysis.</p><p>Glucose polymers were introduced to replace glucose-containing solutions by offering the possible advantages of decreased absorption of solute and increased ultrafiltration for a longer period of time.</p><p>The use of a glucose polymer as an osmotic agent is particularly appealing as a substitute for glucose solutions, particularly in diabetics, in those who require long dwell, and in patients whose ultrafiltration capacity may need to be enhanced [<a href="#rid9">9-12</a>]. The reduced carbohydrate load also may provide some long-term metabolic advantage. This was suggested by one randomized, controlled trial in which 251 diabetic patients were assigned to a control group (dialyzed using standard dextrose solution) or to a low-dextrose treatment group (dialyzed using a combination of dextrose-based solutions, <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>, and amino acids) [<a href="#rid13">13</a>]. At six months, by intention-to-treat analysis, the mean glycated hemoglobin (HbA1C) was improved in the treatment group but not in the control group, with a resulting 0.5 percent difference between groups (95% CI 0.1-0.8). There were also improvements in serum triglycerides, very-low-density lipoprotein (VLDL), and apolipoprotein B in the treatment, but not control, group.</p><p>However, there were more deaths and serious adverse events in the treatment group, many of which were related to volume overload. There were 5 deaths in the control group and 11 in the intervention group. These data suggest that, although low-dextrose dialysate may improve metabolic parameters, volume status should be followed closely.</p><p>The most commonly used glucose polymer is a 7.5 percent solution. The blood concentrations of maltose, maltotriose, and other oligo/polysaccharides have been shown to increase with these agents, possibly resulting in adverse reactions. Several studies, for example, have reported a relatively high incidence of cutaneous reactions (approximately 15 percent) [<a href="#rid14">14</a>].</p><p>The reported incidence of culture-negative peritonitis with glucose polymer solutions ranges from 9 to nearly 50 percent. This is thought to be due to contamination of some batches with a bacterial wall breakdown product, peptidoglycan. The manufacturer subsequently had a voluntary recall of the suspect batches of dialysate, with a resultant decrease in incidence of the peritonitis [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p>However, a systematic review of five randomized trials (607 patients) showed no increase in the risk of peritonitis with <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> [<a href="#rid16">16</a>].</p><p>In addition, both <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> and maltose can interfere with or cause falsely elevated glucose results, possibly leading to inappropriate therapy [<a href="#rid17">17-19</a>]. Thus, the labeling for icodextrin dialysate includes a warning that "blood glucose monitoring must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose."</p><p>In one retrospective study, the use of <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> was associated with a lower risk of technique failure related to noncompliance and mortality [<a href="#rid20">20</a>]. In the systematic review cited above, in three randomized trials (290 patients), icodextrin did not alter risk of technique failure; however, none of the included trials were sufficiently powered to show such a difference, and the follow-up time was short [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H125248418"><span class="h4">Polypeptides</span><span class="headingEndMark"> — </span>Polypeptides may be used as osmotic agents by the hydrolysis of a 5 percent solution of a milk protein with the enzymes trypsin and chymotrypsin [<a href="#rid21">21</a>]. Compared with a 2.5 percent glucose solution, this polypeptide solution yielded twice the ultrafiltrate volume after one hour of dwell. Furthermore, only 3 percent of the peptide was absorbed from the solution. In another study, 10 stable continuous ambulatory peritoneal dialysis (CAPD) patients received either 1 percent peptide with 1.36 percent glucose (osmolality of 381 mosmol/kg) or 2.27 percent glucose (osmolality of 404 mosmol/kg) [<a href="#rid22">22</a>]. The peptide solution was well tolerated, resulting in a similar clearance as the 2.27 percent glucose solution. Furthermore, there were no irritant effects of the peptide solution on the peritoneum, and the plasma amino acid profile was similar in both groups. Thus, short-chain polypeptides were absorbed less than glucose, and their ultrafiltration capacity was similar to 2.27 percent glucose. However, long-term studies are needed to evaluate the effects of peptide on the nutritional status of peritoneal dialysis patients.</p><p class="headingAnchor" id="H125248433"><span class="h4">Dextrans</span><span class="headingEndMark"> — </span>Neutral dextran had been tried as an osmotic agent since the 1960s. Initially, 6 percent dextran in <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> was utilized, but this concentration was unable to achieve good ultrafiltration.</p><p>A 10 percent solution provided good ultrafiltration, but 40 to 60 percent of dextran was absorbed over a six-hour dwell time [<a href="#rid23">23</a>]. Accumulation of dextran in the body can result in blockage of the reticuloendothelial system; thus, it is <strong>not</strong> considered a suitable alternative for <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Low-molecular-weight agents</span><span class="headingEndMark"> — </span>Low-molecular-weight agents, such as dextrose (eg, glucose-containing solutions), amino acids, xylitol, and glycerol, have weights of 90 to 200 DA. Among these agents, dextrose is the most commonly used.</p><p class="headingAnchor" id="H369050792"><span class="h4">Glucose-containing solutions</span><span class="headingEndMark"> — </span>Glucose is the most commonly utilized osmotic agent in peritoneal dialysis. It comes in three different dextrose monohydrate concentrations: 1.5, 2.5, and 4.25 percent (see below).</p><p>Glucose is not the ideal osmotic agent, because it is easily absorbed, leading to short-lived ultrafiltration. Its absorption can also lead to several metabolic complications, such as hyperinsulinemia, hyperglycemia, hyperlipidemia, and weight gain [<a href="#rid24">24</a>]. Furthermore, the high glucose concentration, low pH, and glucose degradation products (GDPs) of these solutions can affect peritoneal host defense mechanisms by inhibiting phagocytosis and bactericidal activity due in part to overall bioincompatibility [<a href="#rid25">25</a>].</p><p><a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a> with neutral pH and low GDPs have been developed in an attempt to improve their biocompatibility [<a href="#rid26">26,27</a>]. The use of such solutions may preserve daily urine volume, though not necessarily residual kidney function [<a href="#rid28">28,29</a>]. Residual kidney function in this setting is defined as solute (eg, urea and/or creatinine) clearance.</p><p>One multicenter, randomized trial compared biocompatible dialysate with conventional dialysate among 185 peritoneal dialysis patients with residual kidney function [<a href="#rid28">28</a>]. At two years, there was no difference in the rate of decline in kidney function. However, the use of the biocompatible solution associated with a decreased risk of anuria (adjusted hazard ratio [HR] 0.36, 95% CI 0.13-0.96) and a decreased rate of peritonitis (0.30 versus 0.49 episodes per patient-year) compared with conventional dialysate.</p><p>A randomized, open-label study compared three biocompatible dialysate solutions to conventional dialysate solution among 150 incident CAPD patients [<a href="#rid29">29</a>]. At 12 months, patients who used biocompatible solutions had better preservation of daily urine volume compared with those who used a conventional dialysate solution (959 versus 798 mL/day), but there was no difference between groups in the rate of decline of residual kidney function.</p><p>One retrospective study of over 2000 patients has suggested a survival benefit associated with a neutral pH low-GDP solution [<a href="#rid27">27</a>]. Randomized, prospective studies are required to accurately determine the possible survival benefits associated with this solution [<a href="#rid30">30,31</a>].</p><p>The main advantage of dextrose is that it is cheap, safe, and easily available. Furthermore, nephrologists are comfortable using dextrose solutions as they have been in the market for a long time. To date, no other osmotic agent has proven superior to dextrose-containing solutions.</p><p class="headingAnchor" id="H369050798"><span class="h4">Amino acid-containing solutions</span><span class="headingEndMark"> — </span>Nutrition is being increasingly recognized as an important predictor of outcome in dialysis patients [<a href="#rid32">32</a>] (see  <a class="medical medical_review" href="/d/html/1855.html" rel="external">"Nutritional status and protein intake in patients on peritoneal dialysis"</a>). Malnutrition is common in peritoneal dialysis patients [<a href="#rid33">33</a>] and has been associated with higher mortality and higher hospitalization rates (see  <a class="medical medical_review" href="/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis"</a>). Whereas several factors are responsible for the low albumin levels in dialysis patients, peritoneal dialysis patients tend to lose significant amounts of protein in the dialysate. It is estimated that up to 15 g of protein and 2 to 4 g of amino acids per day may be lost [<a href="#rid34">34-36</a>].</p><p>Amino acid-containing <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> have therefore been utilized to possibly improve nutritional status in peritoneal dialysis patients. The rationale behind this approach was that the absorbed amino acids from the peritoneal dialysis solution might help contribute to protein synthesis [<a href="#rid37">37</a>].</p><p>However, early experiences with amino acid solutions were not very successful, with little to no nutritional benefit evident in studied patients. One explanation for the lack of benefit is that earlier amino acid solutions were not well designed for peritoneal dialysis. By comparison, subsequent studies found that 1.1 percent amino acid solutions are as effective an osmotic agent as 1.36 percent dextrose solutions [<a href="#rid38">38</a>]. Such studies have also shown optimal utility when amino acids were administered with a nonprotein energy source.</p><p>The amino acid solution used in these studies was a 1.1 percent solution of a combination of essential amino acids and some nonessential amino acids (Nutrineal). The pH of this solution is 6.7, and osmolality is 365 mosmol/kg [<a href="#rid39">39</a>]. In various studies, this solution has been shown to improve the nutritional status of dialysis patients [<a href="#rid40">40</a>]. The common side effects include worsening of acidosis and a rise in blood urea nitrogen (BUN).</p><p>The following guidelines should be considered when prescribing amino acid <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> [<a href="#rid41">41</a>] (see  <a class="medical medical_review" href="/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>They are indicated for use only in malnourished or diabetic patients and/or those with recurrent peritonitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 1.1 percent amino acid solution consisting of predominantly essential amino acids (required by dialysis patients) should be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sufficient concurrent alternative caloric intake should be guaranteed.</p><p></p><p class="headingAnchor" id="H369050804"><span class="h4">Xylitol-containing solution</span><span class="headingEndMark"> — </span>Xylitol has been tried as an osmotic agent in diabetic patients. A preliminary study found that its use helped decrease metabolic complications of diabetes, as well as blood glucose levels [<a href="#rid42">42</a>]. However, it is not used, because of several potentially serious side effects, including lactic acidosis, hyperuricemia, carcinogenicity, and deteriorating liver function.</p><p class="headingAnchor" id="H369050810"><span class="h4">Glycerol-containing solution</span><span class="headingEndMark"> — </span>Glycerol gained interest as an osmotic agent because of its smaller molecular weight, relatively high osmolality per unit mass, and a higher pH than glucose solutions. It was therefore initially proposed as the alternative solution in diabetic patients.</p><p>However, because of rapid diffusion into blood, it produces less ultrafiltration than glucose. In addition, long-term trials found that the insulin requirement was not significantly different after three to four months; furthermore, its regular use may lead to accumulation of glycerol and cause hyperosmolality of the plasma and hypertriglyceridemia. Thus, glycerol solutions have a limited role in diabetic patients [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Buffers</span><span class="headingEndMark"> — </span>Three different agents have been used as buffers to control acidosis in peritoneal dialysis patients. These are acetate, lactate, and bicarbonate [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Lactate</span><span class="headingEndMark"> — </span>Lactate is a commonly used agent to control acidosis [<a href="#rid26">26,45</a>]. It is sometimes associated with inflow pain. Furthermore, occasional, excessive absorption of lactate may lead to encephalopathy. Nonetheless, a lactate buffer is generally quite safe. It is commercially available in concentrations of 35 and 40 mmol/L.</p><p class="headingAnchor" id="H9"><span class="h3">Acetate</span><span class="headingEndMark"> — </span>Acetate controls the metabolic acidosis of chronic uremia as well as lactate; however, the major drawback is that acetate frequently causes pain during inflow, as well as sclerosing peritonitis, the latter leading to poor ultrafiltration.</p><p class="headingAnchor" id="H10"><span class="h3">Bicarbonate</span><span class="headingEndMark"> — </span>Compared with other buffers, bicarbonate controls acidosis in a more physiologic fashion. However, it is not compatible with calcium- and magnesium-containing solutions, particularly if stored for a prolonged period. This problem can be circumvented by using two separate bags (one containing bicarbonate and the other containing calcium and magnesium), which mix together at the time of infusing the solutions.</p><p>However, this procedure was cumbersome for patients and did not gain popularity. Different concentrations of bicarbonate have been mixed with lactate, with variable results [<a href="#rid46">46-52</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Electrolytes</span><span class="headingEndMark"> — </span>Commercially available solutions contain sodium, magnesium, calcium, and chloride. In some settings, minerals like iron pyrophosphate [<a href="#rid53">53</a>] or <a class="drug drug_general" data-topicid="8574" href="/d/drug information/8574.html" rel="external">iron dextran</a> [<a href="#rid54">54</a>] have also been added to the <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> (see  <a class="medical medical_review" href="/d/html/1943.html" rel="external">"Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)"</a> and  <a class="medical medical_review" href="/d/html/1953.html" rel="external">"Treatment of iron deficiency in patients on dialysis"</a>). In addition, potassium can be added to the peritoneal dialysis solution.</p><p class="headingAnchor" id="H12"><span class="h3">Sodium</span><span class="headingEndMark"> — </span>The sodium concentration in <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> varies from 130 to 137 mmol/L. In North America, the sodium concentration of the dialysate is principally 132 mmol/L. Since fluid removal with peritoneal dialysis is mainly by convection, water removal from the plasma exceeds sodium removal, thereby possibly leading to hypernatremia. Thus, the relatively low sodium concentration in the peritoneal dialysis fluid helps offset the predilection for hypernatremia. Nomograms are available to predict net sodium removal, adjusted for glucose concentration of the solution.</p><p class="headingAnchor" id="H13"><span class="h3">Calcium</span><span class="headingEndMark"> — </span>In the 1970s, the most commonly used calcium concentration in <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> was 1.75 mmol/L. The optimal peritoneal dialysis calcium concentration is unclear. Hypercalcemia is common in patients using 1.75 mmol/L of calcium in the dialysate, which is due to the concurrent administration of calcium-containing phosphate binders and vitamin D analogs. (See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>.)</p><p>Thus, an increasing number of centers are now using low-calcium concentrations in the dialysate, which can help in the treatment of hyperphosphatemia with calcium-containing phosphate binders. Studies have shown that lower dialysate calcium (1.25 mmol/L) seems to be safe in the majority of patients [<a href="#rid55">55</a>]. However, hypocalcemia may develop in some patients, particularly in those with poor compliance with calcium-containing phosphorus binders [<a href="#rid56">56,57</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Magnesium</span><span class="headingEndMark"> — </span>Hypermagnesemia is a frequent occurrence in peritoneal dialysis patients. Available <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> contain magnesium at concentrations of 0.5 to 1.5 mEq/L. In most studies, the use of 1.5 mEq/L of magnesium in the dialysate solution resulted in hypermagnesemia. Since persistently elevated magnesium levels may cause bone disease, the 0.5 mEq/L concentration is therefore more commonly used to optimize the serum magnesium concentration. A zero-dialysate magnesium concentration has also been attempted to allow the use of oral magnesium salt as an additional phosphate binder [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Potassium</span><span class="headingEndMark"> — </span>Potassium is usually not added in the commercial dialysate; potassium concentration in commercially available dialysate can vary from 0 to 2 mEq/L. Zero-potassium dialysate tends to maintain serum potassium around 4 mEq/L. Interestingly, 10 to 36 percent of peritoneal dialysis patients develop hypokalemia, which could be corrected by adding 1 to 4 mEq/L of potassium to the dialysate, as required. However, a strongly preferred method is to supplement potassium orally.</p><p class="headingAnchor" id="H16"><span class="h1">AVAILABLE DEXTROSE-BASED SOLUTIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a> are available in different volumes, dextrose concentrations, and formulations.</p><p class="headingAnchor" id="H17"><span class="h2">Volume</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a> are commonly available in 1, 2, 2.5, 3, 5, and 6 liter bags. In the United States, these bags were initially available in glass bottles, but they are currently commercially packaged in collapsible plastic bags.</p><p class="headingAnchor" id="H18"><span class="h2">Dextrose concentrations</span><span class="headingEndMark"> — </span>Three different dextrose concentrations are available: 1.5, 2.5, and 4.25 percent dextrose solutions. The osmolality of these solutions is 346, 396, and 485, respectively. The adequate management of volume status in a peritoneal dialysis patient involves alternating the different concentrations of dextrose-containing solutions to achieve dry weight and blood pressure control.</p><p class="headingAnchor" id="H19"><span class="h2">Formulations</span><span class="headingEndMark"> — </span>Different peritoneal dialysis formulations are commonly used and are available with different concentrations of dextrose.</p><p class="headingAnchor" id="H20"><span class="h3">Standard solution</span><span class="headingEndMark"> — </span>The standard solution contains 132 mEq/L of sodium along with 3.5 mEq/L calcium, 1.5 mEq/L magnesium, 35 mEq/L lactate, and 102 mEq/L of chloride  (<a class="graphic graphic_table graphicRef78759" href="/d/graphic/78759.html" rel="external">table 1</a>). Although this formulation is commonly referred to as the standard solution, this is not necessarily the most commonly prescribed or the best available formulation. The use of the standard solution has been found to be associated with hypermagnesemia and hypercalcemia, particularly if the patients are on high doses of calcium-containing phosphate binders. (See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Modified solutions</span><span class="headingEndMark"> — </span>The most commonly used modifications to <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> are low-magnesium (0.5 mEq/L) and low-calcium (2.5 mEq/L) dialysate  (<a class="graphic graphic_table graphicRef51006" href="/d/graphic/51006.html" rel="external">table 2</a>) [<a href="#rid35">35,36</a>]. Another modification that is available commercially contains low-magnesium (0.5 mEq/L), high-calcium (3.5 mEq/L), and high-lactate concentration.</p><p>These various formulations allow clinicians to tailor and individualize the peritoneal dialysis prescription based upon an individual's electrolyte and metabolic profile.</p><p class="headingAnchor" id="H22"><span class="h2">Other additives</span><span class="headingEndMark"> — </span>Several other additives are often added to the peritoneal dialysis fluid in certain clinical situations. Some of the commonly used additives include insulin, heparin, and antibiotics:</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin is frequently added to <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> in diabetics to help control hyperglycemia and offset the glucose load from the dextrose-containing solutions. Intraperitoneal insulin has been found to be as good as subcutaneous insulin in the management of diabetes in peritoneal dialysis patients. (See  <a class="medical medical_review" href="/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heparin is frequently added to prevent the formation of fibrin in the peritoneal dialysis fluid. This is particularly important during peritonitis episodes, when there is increased fibrin production, as well as deposition of debris, which could lead to obstruction of the peritoneal dialysis catheter. Intraperitoneal heparin does not lead to systemic anticoagulation in these patients. (See  <a class="medical medical_review" href="/d/html/1883.html" rel="external">"Noninfectious complications of peritoneal dialysis catheters"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics are added to the peritoneal fluid to treat peritonitis. They are usually well tolerated, and their absorption through the peritoneal membrane is enhanced during episodes of peritonitis. (See  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H22270358"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of dialysate</strong> – <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a> primarily consist of water, osmotic agents, electrolytes, and minerals. (See <a class="local">'Ideal solution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osmotic agents</strong> – Osmotic agents allow net water removal by altering the osmotic pressure gradient between the peritoneal dialysis solution and plasma water. Dextrose is the most commonly used osmotic agent. Available dextrose concentrations include 1.5, 2.5, and 4.25 percent solutions. Amino acids may be used as an alternative to dextrose to improve nutritional status in peritoneal dialysis patients. (See <a class="local">'Low-molecular-weight agents'</a> above and <a class="local">'Dextrose concentrations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buffers</strong> – Buffers used to control acidosis include acetate, lactate, and bicarbonate. Lactate buffers are most commonly used and are commercially available in concentrations of 35 and 40 mmol/L. Acetate-based buffers cause pain during inflow and have been associated with sclerosing peritonitis. Bicarbonate-based buffers are not compatible with calcium- and magnesium-containing solutions but can be mixed together immediately before use without problems. (See <a class="local">'Buffers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolyte concentrations</strong> – Dialysate contains sodium, calcium, magnesium, and potassium in varying concentrations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sodium</strong> – The sodium concentration in <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> varies from 130 to 137 mmol/L. Nomograms are available to predict net sodium removal. (See <a class="local">'Sodium'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcium</strong> – The optimal peritoneal dialysis calcium concentration is unclear. Many centers use low-calcium concentrations (ie, 1.25 mmol/L), which can help in the treatment of hyperphosphatemia with calcium-containing phosphate binders. Hypocalcemia may develop in some patients who use low-calcium dialysate, particularly those that are noncompliant with calcium-containing phosphate binders. (See <a class="local">'Calcium'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Magnesium</strong> – The magnesium concentrations range from 0.5 to 1.5 mEq/L; the 0.5 mEq/L concentration is more commonly used since higher concentrations may cause hypermagnesemia. (See <a class="local">'Magnesium'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Potassium </strong>– Potassium is usually not present in the commercial dialysate. Zero-potassium dialysate tends to maintain serum potassium around 4 mEq/L, although some patients may develop hypokalemia. Hypokalemia <strong>could</strong> be corrected by the addition of 1 to 4 mEq/L of potassium to the dialysate, but the strongly preferred method is to supplement potassium orally. (See <a class="local">'Potassium'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dextrose-based solutions</strong> – <a class="drug drug_general" data-topicid="113932" href="/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a> are commonly available in 1, 2, 2.5, 3, 5, and 6 liter bags. Three different dextrose concentrations are available: 1.5, 2.5, and 4.25 percent. (See <a class="local">'Available dextrose-based solutions'</a> above and <a class="local">'Volume'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">Icodextrin</a><strong> and spurious hyperglycemia</strong> – Icodextrin-containing solutions can cause falsely elevated glucose levels. In patients using icodextrin, blood glucose monitoring must be done with glucose-specific methods to prevent falsely elevated levels and subsequent inappropriate treatment of presumed hyperglycemia. (See <a class="local">'High-molecular-weight agents'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Feriani, M, La Greca, et al. CAPD Systems and Solutions. In: Textbook of Peritoneal Dialysis, Gokal, R, Nolph, KD (Eds), Kluwer Academic Publishers, Netherlands 1994.</li><li><a class="nounderline abstract_t">Raja RM, Kramer MS, Manchanda R, et al. Peritoneal dialysis with fructose dialysate. Prevention of hyperglycemia and hyperosmolality. Ann Intern Med 1973; 79:511.</a></li><li><a class="nounderline abstract_t">Bischel MD, Barbour BH. Peritoneal dialysis with sorbitol versus dextrose dialysate. Clinical findings and alterations of blood and cerebrospinal fluid. Nephron 1974; 12:449.</a></li><li><a class="nounderline abstract_t">Matthys E, Dolkart R, Lameire N. Extended use of glycerol containing dialysate in diabetic CAPD patients. Perit Dial Bull 1987; 7:10.</a></li><li><a class="nounderline abstract_t">McIntyre CW. Update on peritoneal dialysis solutions. Kidney Int 2007; 71:486.</a></li><li><a class="nounderline abstract_t">Vanholder RC, Lameire NH. Osmotic agents in peritoneal dialysis. Kidney Int Suppl 1996; 56:S86.</a></li><li><a class="nounderline abstract_t">Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.</a></li><li><a class="nounderline abstract_t">Gokal R. Peritoneal dialysis solutions: nutritional aspects. Perit Dial Int 1997; 17 Suppl 3:S69.</a></li><li><a class="nounderline abstract_t">Stein A, Peers E, Hattersley J, et al. Clinical experience with icodextrin in CAPD patients. Perit Dial Int 1994; 14 Suppl:51.</a></li><li><a class="nounderline abstract_t">Lee JH, Reddy DK, Saran R, et al. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 2000; 20:643.</a></li><li><a class="nounderline abstract_t">Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862.</a></li><li><a class="nounderline abstract_t">Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546.</a></li><li><a class="nounderline abstract_t">Li PK, Culleton BF, Ariza A, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol 2013; 24:1889.</a></li><li><a class="nounderline abstract_t">Diaz-Buxo JA, Passlick-Deetjen J, Gotloib L. Potential hazards of polyglucose. ASAIO J 2001; 47:602.</a></li><li><a class="nounderline abstract_t">Seow YY, Iles-Smith H, Hirst H, Gokal R. Icodextrin-associated peritonitis among CAPD patients. Nephrol Dial Transplant 2003; 18:1951.</a></li><li><a class="nounderline abstract_t">Cho Y, Johnson DW, Badve S, et al. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2013; 28:1899.</a></li><li><a class="nounderline abstract_t">Baxter Extraneal hypoglycemia testing program is condition of FDA approval. "The Pink Sheet" 2003; 65:6.</a></li><li><a class="nounderline abstract_t">Riley SG, Chess J, Donovan KL, Williams JD. Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid. BMJ 2003; 327:608.</a></li><li><a class="nounderline abstract_t">Floré KM, Delanghe JR. Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int 2009; 29:377.</a></li><li><a class="nounderline abstract_t">Han SH, Ahn SV, Yun JY, et al. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2012; 27:2044.</a></li><li><a class="nounderline abstract_t">Klein E, Ward RA, Williams TE, Feldhoff PW. Peptides as substitute osmotic agents for glucose in peritoneal dialysate. ASAIO Trans 1986; 32:550.</a></li><li><a class="nounderline abstract_t">Imholz AL, Lameire N, Faict D, et al. Evaluation of short-chain polypeptides as an osmotic agent in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1994; 14:215.</a></li><li><a class="nounderline abstract_t">Hain H, Schütte W, Pustelnik A, et al. Ultrafiltration and absorption characteristics of hydroxyethylstarch and dextran during long dwell peritoneal dialysis exchanges in rats. Adv Perit Dial 1989; 5:28.</a></li><li><a class="nounderline abstract_t">Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564.</a></li><li><a class="nounderline abstract_t">Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: saint or sinner? Perit Dial Int 2005; 25:415.</a></li><li><a class="nounderline abstract_t">Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408.</a></li><li><a class="nounderline abstract_t">Lee HY, Park HC, Seo BJ, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25:248.</a></li><li><a class="nounderline abstract_t">Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097.</a></li><li><a class="nounderline abstract_t">Lui SL, Yung S, Yim A, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60:966.</a></li><li><a class="nounderline abstract_t">Woodrow G. Can biocompatible dialysis fluids improve outcomes in peritoneal dialysis patients? Perit Dial Int 2005; 25:230.</a></li><li><a class="nounderline abstract_t">Diaz-Buxo JA, Gotloib L. Agents that modulate peritoneal membrane structure and function. Perit Dial Int 2007; 27:16.</a></li><li><a class="nounderline abstract_t">Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50:343.</a></li><li><a class="nounderline abstract_t">Young GA, Kopple JD, Lindholm B, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17:462.</a></li><li><a class="nounderline abstract_t">Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int 1981; 19:593.</a></li><li><a class="nounderline abstract_t">Young GA, Brownjohn AM, Parsons FM. Protein losses in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1987; 45:196.</a></li><li><a class="nounderline abstract_t">Bergström J, Fürst P, Alvestrand A, Lindholm B. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int 1993; 44:1048.</a></li><li><a class="nounderline abstract_t">Jones MR, Gehr TW, Burkart JM, et al. Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 1998; 18:210.</a></li><li><a class="nounderline abstract_t">Shockley TR, Martis L, Tranaeus AP. New solutions for peritoneal dialysis in adult and pediatric patients. Perit Dial Int 1999; 19 Suppl 2:S429.</a></li><li><a class="nounderline abstract_t">Garosi G, Gaggiotti E, Monaci G, et al. Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit. Perit Dial Int 1998; 18:610.</a></li><li><a class="nounderline abstract_t">Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47:1148.</a></li><li><a class="nounderline abstract_t">Faller B. Amino acid-based peritoneal dialysis solutions. Kidney Int Suppl 1996; 56:S81.</a></li><li><a class="nounderline abstract_t">Bazzato G, Coli U, Landini S, et al. Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients? Trans Am Soc Artif Intern Organs 1982; 28:280.</a></li><li><a class="nounderline abstract_t">Heaton A, Ward MK, Johnston DG, et al. Evaluation of glycerol as an osmotic agent for continuous ambulatory peritoneal dialysis in end-stage renal failure. Clin Sci (Lond) 1986; 70:23.</a></li><li><a class="nounderline abstract_t">Feriani M. Buffers: bicarbonate, lactate and pyruvate. Kidney Int Suppl 1996; 56:S75.</a></li><li><a class="nounderline abstract_t">Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061.</a></li><li><a class="nounderline abstract_t">Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54:1731.</a></li><li><a class="nounderline abstract_t">Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 1993; 13:296.</a></li><li><a class="nounderline abstract_t">Cancarini GC, Faict D, De Vos C, et al. Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate. Perit Dial Int 1998; 18:576.</a></li><li><a class="nounderline abstract_t">Feriani M, Passlick-Deetjen J, Jaeckle-Meyer I, et al. Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients. Nephrol Dial Transplant 2004; 19:195.</a></li><li><a class="nounderline abstract_t">Montenegro J, Saracho RM, Martínez IM, et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26:89.</a></li><li><a class="nounderline abstract_t">Montenegro J, Saracho R, Gallardo I, et al. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007; 22:1703.</a></li><li><a class="nounderline abstract_t">Ahmad S, Sehmi JS, Ahmad-Zakhi KH, et al. Impact of new dialysis solutions on peritonitis rates. Kidney Int Suppl 2006; :S63.</a></li><li><a class="nounderline abstract_t">Gupta A, Amin NB, Besarab A, et al. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 1999; 55:1891.</a></li><li><a class="nounderline abstract_t">Bastani B, Galley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int 1996; 16:646.</a></li><li><a class="nounderline abstract_t">Sánchez C, López-Barea F, Sánchez-Cabezudo J, et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19:1587.</a></li><li><a class="nounderline abstract_t">Bro S, Brandi L, Daugaard H, Olgaard K. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize? Perit Dial Int 1997; 17:554.</a></li><li><a class="nounderline abstract_t">Weinreich T. Low or high calcium dialysate solutions in peritoneal dialysis? Kidney Int Suppl 1996; 56:S92.</a></li></ol></div><div id="topicVersionRevision">Topic 1905 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Feriani, M, La Greca, et al. CAPD Systems and Solutions. In: Textbook of Peritoneal Dialysis, Gokal, R, Nolph, KD (Eds), Kluwer Academic Publishers, Netherlands 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4748272" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Peritoneal dialysis with fructose dialysate. Prevention of hyperglycemia and hyperosmolality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4842690" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Peritoneal dialysis with sorbitol versus dextrose dialysate. Clinical findings and alterations of blood and cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extended use of glycerol containing dialysate in diabetic CAPD patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299524" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Update on peritoneal dialysis solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914060" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Osmotic agents in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14582053" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9304667" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Peritoneal dialysis solutions: nutritional aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical experience with icodextrin in CAPD patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216553" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920355" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625070" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23949801" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730195" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Potential hazards of polyglucose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937264" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Icodextrin-associated peritonitis among CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23493329" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Baxter Extraneal hypoglycemia testing program is condition of FDA approval</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969932" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19602602" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21968011" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3778766" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Peptides as substitute osmotic agents for glucose in peritoneal dialysate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948230" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of short-chain polypeptides as an osmotic agent in continuous ambulatory peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2484983" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ultrafiltration and absorption characteristics of hydroxyethylstarch and dextran during long dwell peritoneal dialysis exchanges in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7241890" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Glucose absorption during continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16178471" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impact of glucose in peritoneal dialysis: saint or sinner?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15200450" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15981773" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440906" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22835900" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15981769" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Can biocompatible dialysis fluids improve outcomes in peritoneal dialysis patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179504" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Agents that modulate peritoneal membrane structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840260" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nutrition in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901197" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7241892" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Protein losses during peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3574568" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Protein losses in patients receiving continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8264134" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9576371" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406559" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New solutions for peritoneal dialysis in adult and pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932660" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7783413" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of malnourished CAPD patients with an amino acid based dialysate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914059" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Amino acid-based peritoneal dialysis solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6761936" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510801" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Evaluation of glycerol as an osmotic agent for continuous ambulatory peritoneal dialysis in end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914058" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Buffers: bicarbonate, lactate and pyruvate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551418" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9844152" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized long-term evaluation of bicarbonate-buffered CAPD solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8241330" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Short-term clinical study with bicarbonate-containing peritoneal dialysis solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932655" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671057" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538881" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17405794" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080113" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impact of new dialysis solutions on peritonitis rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10231452" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8981540" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15069173" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655154" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914061" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Low or high calcium dialysate solutions in peritoneal dialysis?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
